Ameriprise Financial Inc Disclosed New Quotient Ltd Position

February 15, 2018 - By Kurt Siggers

 Ameriprise Financial Inc Disclosed New Quotient Ltd Position

Investors sentiment decreased to 1.42 in Q3 2017. Its down 6.98, from 8.4 in 2017Q2. It worsened, as 7 investors sold Quotient Limited shares while 12 reduced holdings. 9 funds opened positions while 18 raised stakes. 21.37 million shares or 49.89% less from 42.64 million shares in 2017Q2 were reported.

Jpmorgan Chase & Co has invested 0% in Quotient Limited (NASDAQ:QTNT). Rhumbline Advisers holds 0% or 27,737 shares. Nationwide Fund Advsr invested 0% of its portfolio in Quotient Limited (NASDAQ:QTNT). Acuta Cap Partners Ltd Limited Liability Company has invested 0.5% in Quotient Limited (NASDAQ:QTNT). National Bank Of New York Mellon Corp holds 0% of its portfolio in Quotient Limited (NASDAQ:QTNT) for 61,104 shares. Blackrock Inc invested in 1.66M shares or 0% of the stock. Perceptive Ltd Llc invested 0.7% of its portfolio in Quotient Limited (NASDAQ:QTNT). Ghost Tree Capital Lc reported 187,450 shares or 0.2% of all its holdings. State Common Retirement Fund invested in 13,700 shares or 0% of the stock. Clearbridge Lc invested in 0.18% or 1.67 million shares. Royal Bancorporation Of Canada invested in 4,304 shares or 0% of the stock. Bancshares Of America Corporation De has 1,432 shares. Kamunting Street Cap Mgmt Limited Partnership holds 25,000 shares. Tekla Ltd Limited Liability Company stated it has 118,861 shares. The Nebraska-based Ameritas Prtnrs has invested 0% in Quotient Limited (NASDAQ:QTNT).

Since August 15, 2017, it had 0 buys, and 2 sales for $904,595 activity.

The New Ameriprise Financial Inc Holding in Quotient Ltd

Ameriprise Financial Inc reported SC 13G/A form with the SEC for Quotient Ltd. Access it here: 000119312518045341. As reported by Ameriprise Financial Inc, the filler owns 4.71% or 2,146,681 shares of the Health Care–company.

Quotient Ltd stake is new for [reportingPerson]. Date of activity: December31, 2017. This shows Ameriprise Financial Inc’s positive view for Quotient Ltd.

Quotient Ltd Institutional Sentiment

Filings show 20 investors own Quotient Ltd. The ownership in Q3 2015 is low, at Infinity of the outstanding shares. This is increased by 1432993. 7883365 were owned by these investors. 2 funds opened new Quotient Ltd stakes, 8 increased positions. There were 3 that closed positions and 6 reduced them.

Birchview Capital Lp is an investor bullish on Quotient Ltd, owning 18200 shares as of Q3 2015 for 0.14% of its portfolio. Joseph Edelman Perceptive Advisors Llc owns 776803 shares or 0.83% of its portfolio. MA Cormorant Asset Management Llc have 2.32% of its portfolio for 1119100 shares. Further, Foresite Capital Management Ii Llc reported stake worth 1.15% of its portfolio. The NY Sio Capital Management Llc owns 1580457 shares. Quotient Ltd is 11.42% of its portfolio.

Business Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

SEC Form 13G.

The stock increased 2.54% or $0.1 during the last trading session, reaching $4.03. About 76,646 shares traded. Quotient Limited (NASDAQ:QTNT) has declined 16.87% since February 15, 2017 and is downtrending. It has underperformed by 33.57% the S&P500.

Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $183.72 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.

Quotient Limited (NASDAQ:QTNT) Ratings Coverage

Among 3 analysts covering Quotient (NASDAQ:QTNT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quotient has $30 highest and $12.0 lowest target. $17.25’s average target is 328.04% above currents $4.03 stock price. Quotient had 6 analyst reports since August 11, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $13 target in Wednesday, November 1 report. The stock has “Hold” rating by Zacks on Friday, August 14. UBS maintained Quotient Limited (NASDAQ:QTNT) rating on Wednesday, November 4. UBS has “Buy” rating and $26 target. BTIG Research initiated Quotient Limited (NASDAQ:QTNT) on Thursday, August 31 with “Buy” rating. Jefferies initiated the stock with “Buy” rating in Tuesday, August 11 report. The company was maintained on Tuesday, February 6 by BTIG Research.

More news for Quotient Limited (NASDAQ:QTNT) were recently published by:, which released: “Quotient Limited to Report Continued Progress on the Commercial Scale-Up of …” on July 21, 2017.‘s article titled: “Quotient Limited’s (QTNT) CEO Paul Cowan on Q2 2018 Results – Earnings Call …” and published on October 31, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.